|Videos|December 15, 2015
- Breast Cancer (Issue 2)
- Volume 1
- Issue 2
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Author(s)William Sikov, MD
William Sikov, MD, associate director of Clinical Research, Program in Women
William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.
Articles in this issue
almost 10 years ago
Dr. Carey Anders on Treating Brain Metastases in Breast Canceralmost 10 years ago
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Canceralmost 10 years ago
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Canceralmost 10 years ago
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBCRelated Content
Advertisement
